Clinical trials: Bone Metastasis
Hyperparathyroidism, Secondary
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).
- Trial name
- NCT01932970
- Testing
- Etelcalcetide
- Where
- 40 sites in United States
- Volunteers
- 158 people
- Sponsor
- Amgen
Bone Metastatic Non-small Cell Lung Cancer
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of…
- Trial name
- NCT04325776
- Testing
- AL2846, Zoledronic Acid Injection
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hip Replacement, Primary, Secondary or Post-traumatic Osteoarthrosis
Clinical and Radiological Results of Total Hip Arthroplasty Using a Ceramic Friction Pair
The aim of this study is to assess safety and general performance of total hip arthroplasty, composed of a Meije Duo® femoral stem associated with a Dynacup® cup, and using the friction pair Biolox® Delta Ceramic.
- Conditions
- Hip Replacement, Primary, Secondary or Post-traumatic Osteoarthrosis, Femur Head Necrosis, Congenital Dislocations
- Trial name
- CERAM (NCT02062437)
- Volunteers
- 132 people
- Sponsor
- Stryker Trauma and Extremities
Urothelial Carcinoma
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. This study is a Phase 2 trial evaluating the efficacy of mocetinostat in patients that have advanced urothelial carcinoma that has specific changes in…
- Trial name
- NCT02236195
- Testing
- Mocetinostat
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mirati Therapeutics Inc.
Prostate Cancer
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and…
- Trial name
- NCT02518698
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- United States
- Volunteers
- 1,163 people
- Sponsor
- Bayer
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Prostatic Neoplasms
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
This is an uncontrolled, open-label, non-randomized Phase I study to investigate safety, biodistribution, radiation dosimetry and pharmacokinetics of a single dose of BAY88-8223 in Japanese patients with castration-resistant…
- Trial name
- NCT01565746
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Bayer
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Bone Metastases, Fractures, Bone
EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy
Interventional clinical study to obtain performance and safety data of the EPIONE® device when used for bone percutaneous procedures.
- Conditions
- Bone Metastases, Fractures, Bone, Bone Tumor
- Trial name
- EPIBONE (NCT06376682)
- Testing
- CT-guided bone percutaneous procedure
- Where
- 3 sites in France
- Volunteers
- 34 people
- Sponsor
- Quantum Surgical
Osteopenia, Osteoporosis
FREE Study - Fracture Reduction Evaluation
The primary objective of this study is to compare the effectiveness of standard medical therapy alone to kyphoplasty using the KyphX system for the treatment of acute vertebral body compression fractures.
- Conditions
- Osteopenia, Osteoporosis, Multiple Myeloma, Bone Neoplasms
- Trial name
- NCT00211211
- Testing
- Balloon Kyphoplasty
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Medtronic Spine LLC
Patients With Bone Metastases
PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases
To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection…
- Trial name
- NCT06380881
- Testing
- SHR-2017
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Prostate Cancer, Bone Metastases
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
A phase1 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
- Trial name
- NCT02826382
- Testing
- [68Ga]P15-041
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Five Eleven Pharma, Inc.
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003827
- Testing
- amifostine trihydrate, cytarabine, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ALZA
Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS)
A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma
SOT106 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called LRRC15, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B.
- Conditions
- Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS), Osteosarcoma, Advanced
- Trial name
- NCT07801222
- Testing
- SOT106
- Where
- Moldova
- Volunteers
- 70 people
- Sponsor
- SOTIO Biotech a.s.
Bone Metastases
MR Guided Focused Ultrasound Surgery in the Treatment of Pain From Bone Tumors w/ the ExAblate 2000 Strappable System
A Feasibility Study To Evaluate the Safety and initial Effectiveness of MR guided Focused Ultrasound Surgery in the Treatment of pain resulting from Metastatic Bone Tumors with the ExAblate 2000 strappable system.
- Trial name
- BM005 (NCT03547557)
- Testing
- Exablate 2000 strappable system
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- InSightec
Breast Cancer, Metastases
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.
- Conditions
- Breast Cancer, Metastases, Bone Metastases in Subjects With Advanced Breast Cancer
- Trial name
- NCT00091832
- Testing
- Denosumab, IV Bisphosphonates
- Volunteers
- 255 people
- Sponsor
- Amgen
Prostate Cancer
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
20 patients with invasive castration resistant prostate cancer and radiologically verified metastases will be enrolled into the Phase I Clinical Trial. The trial is a dendritic cell based immunotherapy.
- Trial name
- CryoIT (NCT02423928)
- Testing
- Dendritic cell based cryoimmunotherapy, Cyclophosphamide, ipilimumab
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Alden Cancer Therapy II
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Painful Bone Metastases, Breast Carcinoma
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
This study will evaluate treatment with High Intensity Focused Ultrasound (HIFU)in combination with ThermoDox (liposomal doxorubicin) is safe and effective in reducing pain for patients with painful bone metastases.
- Conditions
- Painful Bone Metastases, Breast Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01640847
- Testing
- High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox
- Sponsor
- Imunon
Pain
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.
- Trial name
- TRAPEZE (NCT00375648)
- Testing
- Zoledronic acid
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals